Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MYO vs ENOV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENOV Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

ENOV Overall Winner 6-Pillar Tally: MYO 1 – 5 ENOV Matrix Metrics: MYO 2 – 8 ENOV

As of Nov 20, 2026, Enovis Corporation (ENOV) is the stronger overall head-to-head candidate over Myomo Inc. (MYO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MYO carries a Unified Composite Score of 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin), whereas ENOV carries 30.0/100 (SELL) at $25.47 (7.3x Forward P/E, 4.0% operating margin).

  • Composite vs. Pillar Nuance: While MYO currently prints a higher short-term Unified Composite Score (40.1/100 SELL vs. ENOV 30.0/100 SELL), ENOV captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (4.0% vs. -21.8% operating margin) and revenue trajectory (+1.8% vs. +22.2% YoY).
  • Defensive Composite Rating Caution: Although ENOV compares more favorably head-to-head, both MYO (40.1/100 SELL) and ENOV (30.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile ENOV trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 54.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MYO vs ENOV
MYO NYSE American
Myomo Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.81
-3.45% 1D
Market Cap $33.7M
TTM Revenue $46M
Forward P/E N/M
Beta / 30D Vol 2.22β · 107% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 25.0 Fund 43.0 Flow 58.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $1.16 · SMA50: $1.32
ENOV NYSE Head-to-Head Winner
Enovis Corporation
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$25.47
-2.9% 1D
Market Cap $1.5B
TTM Revenue $2.31B
Forward P/E 7.3x
Beta / 30D Vol 0.75β · 101% Vol
Unified Composite Score
30.0 / 100 SELL
Tech 15.0 Fund 28.0 Flow 50.0 Mom 21.3
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.2% over 20 days), RSI 54
RSI-14: 54.3 · SMA20: $25.18 · SMA50: $21.30

6-Pillar Scorecard Institutional Category Breakdown (MYO 1 – 5 ENOV)

Columns: Metric · MYO · ENOV
1. Valuation Multiples ENOV
Forward P/E N/M 7.3x
Trailing P/E N/M 7.5x
PEG Ratio N/M 1.90x
EV / Revenue 0.9x 0.7x
2. Growth & Scale ENOV
Revenue Growth (YoY) +22.2% +1.8%
Earnings Growth (YoY) +0.0% +153.1%
TTM Revenue (USD) $46M $2.31B
Market Cap $33.7M $1.5B
3. Profitability & Quality ENOV
Gross Margin 70.1% 61.3%
Operating Margin -21.8% 4.0%
Net Profit Margin -33.1% -22.9%
Return on Equity (ROE) -173.5% -29.9%
4. Balance Sheet & Cash Flow ENOV
Cash Generation (TTM) -$9.1M $387M EBITDA
Cash Flow Margin -20.0% 16.8% EBITDA Mgn
Net Cash / Leverage $8.9M Net Debt (3.44x D/E) $25.88 Book/Sh · -29.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MYO
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 266.0% (81st %ile) 65.6% (43rd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat ENOV
OpEx & R&D Intensity N/A 57.3% of Rev ($1.32B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MYO (2) vs ENOV (8)
Institutional Metric MYO ENOV Criterion Row Edge
Market Capitalization
Scale
$33.7M $1.5B Larger Scale ENOV
Trailing P/E Ratio
Valuation
N/M 7.5x Lower Multiple ENOV
Forward P/E Ratio
Valuation
N/M 7.3x Lower Multiple ENOV
Revenue Growth (YoY)
Growth
+22.2% +1.8% Higher Growth MYO
Operating Margin (TTM)
Profitability
-21.8% 4.0% Higher Margin ENOV
Net Profit Margin
Profitability
-33.1% -22.9% Higher Margin ENOV
Return on Equity (ROE)
Capital Efficiency
-173.5% -29.9% Higher ROE ENOV
52-Week Range Position
Momentum
16% ($1–$2) 59% ($17–$32) Stronger Trend ENOV
Beta / 30D Volatility
Risk Regime
2.22β · 107% Vol 0.75β · 101% Vol Lower Realized Risk ENOV
Unified Institutional Score
Composite Signal
40.1 / 100 (SELL) 30.0 / 100 (SELL) Higher Composite MYO
Trailing 12M Revenue (USD)
Operating Scale
$46M $2.31B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
70.1% 61.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev 1.90x PEG · 0.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.1M ($8.9M Net Debt (3.44x D/E)) $387M EBITDA ($25.88 Book/Sh · -29.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENOV +51.49 pp
MYO: -33.52% · ENOV: +17.97%
3M Horizon ENOV +42.68 pp
MYO: -41.65% · ENOV: +1.03%
6M Horizon ENOV +27.31 pp
MYO: -22.02% · ENOV: +5.29%
1Y Horizon MYO +18.56 pp
MYO: +12.3% · ENOV: -6.26%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MYO vs ENOV. Trailing 12-month operating profitability (MYO -21.8% vs ENOV 4.0%) and valuation multiples (MYO N/M vs ENOV 7.3x Forward P/E) are benchmarked directly in Pillar 4 below.

MYO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$46M
Gross Margin70.1%
Op. Margin-21.8%
ROE / Fwd P/E-173.5% · N/M
ENOV ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.31B
Gross Margin61.3%
Op. Margin4.0%
ROE / Fwd P/E-29.9% · 7.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 266.0%
IV Percentile 81st %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 65.6%
IV Percentile 43rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ENOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MYO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $33.7M market capitalization and -21.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ENOV Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.5B market capitalization and 4.0% operating margin.
OpEx & R&D Reinvestment 57.3% of Rev ($1.32B)
90D Engineering Disclosures 0 Published

Investor FAQ MYO vs ENOV Key Questions & Quantitative Answers

As of Nov 20, 2026, Enovis Corporation (ENOV) is the stronger overall head-to-head candidate over Myomo Inc. (MYO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MYO carries a Unified Composite Score of 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin), whereas ENOV carries 30.0/100 (SELL) at $25.47 (7.3x Forward P/E, 4.0% operating margin). Composite vs. Pillar Nuance: While MYO currently prints a higher short-term Unified Composite Score (40.1/100 SELL vs. ENOV 30.0/100 SELL), ENOV captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (4.0% vs. -21.8% operating margin) and revenue trajectory (+1.8% vs. +22.2% YoY). Defensive Composite Rating Caution: Although ENOV compares more favorably head-to-head, both MYO (40.1/100 SELL) and ENOV (30.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile ENOV trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 54.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ENOV leads the Growth & Scale pillar: MYO posts +22.2% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (70.1% gross margin, -21.8% operating margin), compared with ENOV at +1.8% YoY revenue growth and +153.1% YoY earnings growth on $2.31B TTM revenue (61.3% gross margin, 4.0% operating margin). On trailing 12-month operating scale, MYO generates $46M in USD-normalized revenue versus $2.31B for ENOV. In operating R&D and SG&A reinvestment, MYO deploys N/A (0 90-day corporate R&D disclosures) versus 57.3% of Rev ($1.32B) (0 disclosures) for ENOV.

ENOV screens cheaper on headline valuation multiples. MYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-20.0% FCF margin), whereas ENOV trades at 7.3x Forward P/E, 7.5x Trailing P/E, 1.90x PEG, and 0.7x EV/Revenue (16.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MYO (-173.5% ROE) versus ENOV (-29.9% ROE) capital efficiency.

In options market volatility and institutional positioning, MYO carries 266.0% implied volatility (81st %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.22β · 107% Vol realized risk). By comparison, ENOV carries 65.6% implied volatility (43rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.75β · 101% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.